Promomed

Promomed Group of Companies (Promomed DM LLC) is a representative of the Russian pharmaceutical industry, a participant in the national drug safety system. Develops, manufactures and promotes medicinal products, focusing on optimizing the safety profile of the therapy of the most important, including socially significant diseases.

Due to the biotechnological platform of Biochemist JSC, which operates in full compliance with GMP standards (from the English Good Manufacturing Practice, good manufacturing practice), the company is able to develop and produce any innovative drugs.

Products

As of August 2022, the Promomed portfolio has more than 250 names of drugs, 80% of which are included in the VED list. Some of the drugs are included in the list of methodological recommendations "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)" of the Ministry of Health of the Russian Federation. Active work is underway to form a special antique portfolio, which has already included drugs aimed at treating COVID-19 directly of any severity, modern antibiotics and effective anticoagulants. Antique portfel is represented by such products as Esperavir, Areplivir, Enoparin and others.

History

2023

Plan to establish a biotechnology development center in conjunction with Mordovian State University

The Promomed Group of Companies, together with the Mordovian State University, will create a Federal Center for the Development of Biotechnology. Promomed announced this on July 6, 2023.

The discussion of the creation of the Federal Center for the Development of Biotechnology in Saransk was the key topic of the working meeting of the Head of Mordovia Artem Zdunov and the Minister of Science and Higher Education of Russia Valery Falkov, which was also attended by the Chairman of the Board of Directors of the Promomed Group of Companies Pyotr Beliy and the rector of the Mordovian State University named after N.P..P. Ogarev dmitry Glushko.

Independence from foreign raw materials in the production of drugs is a priority. The future center for the development of biotechnology will ensure a full production cycle, guarantees the drug safety of Russia, - said Artem Zdunov.

The center will provide an opportunity for tripartite interaction between the state, business and science, including with young scientists who create startups. They will be able to work, conduct research and receive data in one place.

We stand in the creation of the Center as an industrial partner. At the same time, the results of the Center's activities will be available to all interested parties. This is such a partnership in the name of patient health. Biologics will be created at the Center, which opens a new era in the treatment of a large group of diseases that were previously considered incurable. By combining our efforts, we will be able to make a real breakthrough in the creation of new drugs, - Pyotr Beliy is sure.

Plan for the creation of a research center and production of biotechnological products at Technopolice Moscow

The Moscow government and the Promomed group of companies agreed on cooperation in the creation of a research center and the production of biotechnological products on the territory of the Moscow Technopolice Special Economic Zone (SEZ). The corresponding agreement was signed by the head of the Department of Investment and Industrial Policy, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, Vladislav Ovchinsky and Chairman of the Board of Directors of the company Pyotr Beliy.

In the SEZ "Technopolice Moscow" at the site "Pechatniki" it is planned to create a research laboratory with a pilot production site for the development of the latest drugs, scaling technological processes, including original ones. And at the site in Alabushevo, the production of domestic biologics will be opened. The project will ensure the production of analogues of foreign drugs for the treatment of vital diseases, as well as create a solid technological base for the development and release of supernovae of domestic original drugs.

This production will become part of the pharmaceutical cluster of the special economic zone. The research unit will be located at the Pechatniki site, and production will be located at Alabushevo. A plot of 3.2 hectares was allocated for the construction of the enterprise. It is planned to create more than 400 workplaces. Investments in the project will amount to about 4.3 billion rubles, - said Vladislav Ovchinsky.

It is planned that at the first stage the capacity of the pilot production site will be about 250 thousand vials of drugs per year.

With the support of the Moscow Government at the Technopolice Moscow SEZ site, the company is creating a center for a full cycle of production of biotechnological drugs of recent generations. Here we plan to develop a line of biotechnological substances. For drug independence, we need our own innovative drugs next-in-class and first-inclass. It is they who will move us forward. And the signing of this agreement is a significant step in this direction, - commented the chairman of the board of directors of the company Pyotr Beliy.

An employee of the Secretariat of the Ministry of Finance of the Russian Federation was sentenced to 12 years in prison for bribes from Promomed

The Zamoskvoretsky Court of Moscow in April 2023 sentenced to 12 years in a general regime colony an employee of the secretariat of the Minister of Finance Anton Siluanov and the former assistant to the Deputy Prime Minister of the Government Arkady Dvorkovich Anastasia Alekseeva. She was found guilty of receiving two especially large bribes and deprived of orders of merit to the Fatherland.

Alekseeva received bribes from the management of Medpolymerprom and Promomed in the amount of about 5.8 million rubles. in the form of tickets and vacation vouchers in Thailand and the Dominican Republic. In exchange, the official was supposed to help promote drugs. Alekseeva did not admit her guilt.

Promomed bought a controlling stake in Berakhim

In early January 2023, it became known that the Promomed group of companies entered into an agreement to acquire 51% of shares in the chemical-pharmaceutical company Berakhim. Read more here.

2022

Opening of high-tech tablet production for 1.8 billion rubles

On December 17, 2022, on the basis of the Biochemist plant, the production site of the Promomed Group of Companies in Saransk, a high-tech tablet production was opened. This was reported to Zdrav.Expert by representatives of the Promomed Group of Companies. Read more here.

Placement of bonds for 2.5 billion rubles on the Moscow Exchange

On August 19, 2022, PROMOMED DM LLC announced that it had successfully placed the third issue of exchange-traded bonds. Against the background of high interest of investors, the volume of output was increased from 1.5 to 2.5 billion rubles, the coupon rate was 11.50% per annum. Both retail and institutional investors participated in the offering.

The nominal value of one bond is 1,000 rubles. The placement price is 100% of the face value. The circulation period is 1092 days. The coupon period is 182 days. The placement method is an open subscription. The placement took place on the Moscow Exchange, the issue is included in the Third level of the listing. The issue meets the requirements for investing pension savings and insurance reserves.

Funds received from the placement of bonds, the company traditionally invests in the development and expansion of production, as well as in the development and registration of new medicines. As of August 2022, the Promomed strategy is based on the balance of creating its own drugs, as well as developing generics with improved characteristics.

Attracting the market financings through the third issue of exchange-traded bonds will allow us to maintain growth rates, provide patients with new high-quality domestic drugs, and the market - farm substances to strengthen drug independence, countries commented Pyotr Beliy Chairman of the Board of Directors of PROMOMED DM LLC.

2021: Production volume - 89.5 million packages of drugs

The volume of production of Promomed Group of Companies in 2021 amounted to 89.5 million packages of drugs for various purposes.

2020: Placement of bonds worth 1 billion rubles on the Moscow Exchange

In December 2020, Promomed first placed bonds on the Moscow Exchange. According to the results of the Russian manufacturer of drugs from Coronavirus COVID-19 attracted 1 billion rubles.

The coupon rate was fixed at 9.5% per annum. The frequency of payment is 182 days. The guarantor for the release is the production site of the holding JSC Biochemist"." The organizers of the placement are, Raiffeisen Bank bank "" and FC OtkritieUniver capital"."

The placement was absolutely market in nature, - said the chairman of the board of directors of Promomed Pyotr Beliy. - A large number of applications were collected, and we have the right to count on good liquidity of our bonds in the secondary market. In the future, the company will continue to work on improving results.

Russian manufacturer of COVID-19 drug Promomed placed bonds worth 1 billion rubles at the Moscow Exchange

Promomed, according to the company, plans to focus on creating innovative antiviral, antibacterial, endocrinological and oncological drugs. The company's investment program includes not only the development and production of active pharmaceutical substances and finished dosage forms, but also the construction of new laboratories, workshops for the production of oncological drugs, and the expansion of the production of tablet forms. In total, Promomed intends to invest up to 7 billion rubles in development by 2023.

By December 2020, original drugs account for about 30% of manufactured products. In total, there are more than 150 names of drugs in the portfolio. Promomed expects to bring more than 100 new molecules to the market, according to the company's investment memorandum.

By the end of 2020, Promomed is one of three domestic manufacturers of the drug with favipiravir, which is recommended for use in any form of COVID-19.^[1]

2016: Therapeutic Areas of Advanced Drugs

Logo in 2016

As of October 2016, the company was promoting prescription and over-the-counter drugs in several therapeutic areas:

• endocrinology,
• rheumatology,
• neurology,
• urology,
• cardiology
• gynecology.

2015: Joining the Biochemist Plant Group

The plant of JSC Biochemist"" became part of the Promomed group in 2015.

2005: Building a Company

Promo-Med was created in September 2005 by Russian and foreign investors.

Notes